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Spectroscopy One rTMS session in Parkinson’s disease (PD) does not affect neuronal integrity.
 One rTMS session influences membrane turnover, inversely correlated with disease duration.
 The presence of dyskinesias did not influence spectroscopy outcomes.
a b s t r a c t
Objective: To study the effect of Low Frequency repetitive Transcranial Magnetic Stimulation (LF rTMS)
on brain metabolites in late stage Parkinson’s disease (PD) patients (disease duration at least 4 years
and Hoehn and Yahr (1969) score at least 2 in OFF). Several neuroimaging data support a role for pre-
Supplementary Motor Area (pre-SMA) involvement in the pathogenesis of Parkinson’s disease. Proton
magnetic resonance spectroscopy (1H-MRS) measures in vivo metabolites, but results in PD brain remain
conflicting and little is known of the effect of LF rTMS thereupon.
Methods: We investigate the neurochemical profile of the right pre-SMA in 17 late stage PD patients (11
male and 6 female, mean age of 71 years) before and after one session of sham controlled 1 Hz rTMS
(1000 pulses, 16 minutes), focusing on the tNAA/tCr and tCho/tCr ratios.
Results: The tNAA/tCr ratio was unaffected by one session of LF rTMS. We did observe a significant effect
of real LF rTMS on the tCho/tCr ratio, inversely correlated with disease duration, and not related to the
presence of dyskinesias. As expected, one session of LF rTMS did not affect clinical outcome.
Conclusions: LF rTMS at the right pre-SMA in late stage Parkinson’s disease patients does not alter tNAA/
tCr, but influences tCho/tCr ratio, in particular in patients with shorter disease duration.
Significance: Pre-SMA LF rTMS seems to influence membrane turnover, more importantly in patients with
shorter disease duration. Larger LF rTMS treatment studies applying multiple sessions are needed.
 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights
reserved.1. Introduction tion techniques (LF and HF rTMS, deep rTMS, theta burst stimula-Therapeutic management of late stage Parkinson’s disease (PD)
patients remains a huge challenge. Several non-invasive stimula-tion) have been investigated for the modulation of cortical
excitability in Parkinson’s disease and in the treatment of its motor
and nonmotor symptoms (Brys et al., 2016; Cohen et al., 2018;
Lefaucheur et al., 2004; Zamir et al., 2012). In healthy control sub-
jects, motor cortex excitability has been documented to be
decreased by LF rTMS when applied directly over the motor cortex
(Chen et al., 1997). Since hyperactivity of the primary and
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levodopa induced dyskinesias (LID) (Rascol et al., 1998), LF rTMS
has been investigated as a potential noninvasive treatment of LID
with conflicting results (Brusa et al., 2006; Filipovic et al., 2009;
Flamez et al., 2016; Koch et al., 2005; Wagle Shukla et al., 2007).
In a previous trial, we investigated the effect of a single motor cor-
tex LF rTMS session on LID, and to overcome the possible low
potential of single session paradigms on LID, we extended our
study into an accelerated multiple sequential LF rTMS treatment
protocol. We failed to alleviate dyskinesias even in the multiple
session treatment paradigm (Flamez et al., 2016). Since the patho-
physiological mechanisms of levodopa induced dyskinesias in PD
are still not fully unraveled, the ideal cortical rTMS target for the
treatment of LID in PD remains to be determined. Although hyper-
activity of primary (and associated) motor cortices in LID has been
documented (Rascol et al., 1998), there is increasing morphometric
and functional Magnetic Resonance Imaging (fMRI) evidence of
involvement of the prefrontal cortex in the pathophysiology of
LID (Cerasa et al., 2012; Cerasa et al., 2013). Pathological and func-
tional MRI data support a role for the pre-Supplementary Motor
Area (pre-SMA) in the pathogenesis in different stages of Parkin-
son’s disease (Eckert et al., 2006; MacDonald and Halliday, 2002).
A combined resting state fMRI and rTMS study highlights the key
role of the right Inferior Frontal Cortex (IFC) in the cortical-
subcortical network in dyskinetic Parkinson patients, suggesting
an increased connectivity between the right IFC and the right puta-
men in those patients (Cerasa et al., 2015). Moreover, an fMRI
study demonstrated that exposure to levodopa in late stage dysk-
inetic patients not only led to a putaminal hyperactivation, but also
caused an excessive increase in activity in the pre-SMA, highlight-
ing the importance of pre-SMA involvement in late stage PD brain
(Herz et al., 2014). In this study, we chose to investigate whether
we could influence this above mentioned right centered network
by applying inhibitory low frequency rTMS to the anatomically
and functionally connected right pre-SMA.
Proton magnetic resonance spectroscopy (1H-MRS) is a non-
invasive brain imaging technique used to measure in vivo metabo-
lites in the brain. Some of the metabolites can be easily quantified
such as N-acetylaspartate/N-acetylaspartylglutamate (tNAA), cho-
line containing compounds (tCho) and creatine/phosphocreatine
(tCr), reflecting neuronal density and integrity, turnover of cell
membranes and energy metabolism, respectively. Since tCr detec-
tion is easy and concentration is fairly stable under physiological
conditions, it can be used as an internal concentration reference,
expressing neurochemical values as tNAA/tCr and tCho/tCr
(Rackayova et al., 2017). 1H-MRS has been used to study age related
metabolite concentration changes in the normal aging brain (Ding
et al., 2016; Schmitz et al., 2018), and has provided insight in neuro-
chemical mapping in pathological brain, including Parkinson’s
disease (Levin et al., 2014). Conflicting results in early PD studies
(i.e. before 2014), mainly focusing on NAA/Cr and Cho/Cr ratios,
were reviewed by Ciurleo and colleagues providing an overview of
spectroscopy studies in treated and untreated PD patients. Despite
methodological differences, overall, it seems that brain NAA levels
in PD are reduced in cortical-basal ganglia networks, reflecting neu-
ronal loss, and it is suggested that this could be influenced by
dopaminergic therapy or even Deep Brain Stimulation (DBS) of the
SubthalamicNucleus (STN) (Ciurlio et al., 2014).More recent studies
highlight the usefulness ofmeasuringNAA/Cr ratio’s in basal ganglia
network regions (substantia nigra, globus pallidus, prefrontal lobe)
as metabolic markers in early diagnosis of Parkinson’s Disease
(Guan et al., 2017; Wu et al., 2016). Pre-SMA spectroscopy data in
PD brain are less straightforward, even though an fMRI study
revealed increased pre-SMA activation in early stage PD patients
(Eckert et al., 2006). Both disease duration and dopaminergic
treatment seem to play an important role in neurochemicalconcentrations in PD patients’ pre-SMA. Compared to healthy con-
trols, the pre-SMA NAA/Cr and Cho/Cr ratios are normal in early
untreated PD patients (Martin et al., 2008). Pre-SMA NAA/Cr ratios
however are significantly reduced in a more advanced, albeit trea-
ted, PD population (Camicioli et al., 2007). Moreover, it has been
documented that dopaminergic treatment is able to restore motor
cortex Cho/Cr ratio, which is reduced in de novo untreated PD
patients compared to controls (Lucetti et al., 2007).
One recent study in healthy humans demonstrated that one ses-
sion of sham controlled LF rTMS on the left Dorsolateral Prefrontal
Cortex is sufficient to influence the relationship between measures
of tNAA and tCho (Bridges et al., 2018). The effect of rTMS on brain
metabolites has been studied in treatment resistant depression,
including tNAA/tCr ratios, (Baeken et al., 2017) and tinnitus
(Cacace et al., 2017), however, little is known about the effect of
LF rTMS on brain metabolites in late stage PD patients.
Therefore, in our study we chose to evaluate the effect of a sin-
gle sham-controlled LF rTMS session over the right pre-SMA on
tNAA/tCr and tCho/tCr pre-SMA ratios in late stage PD patients,
taking into consideration disease duration and the presence of
dyskinesias, we expected that one real LF rTMS session and not
sham would affect tNAA/tCr and tCho/tCr ratios.2. Methods
2.1. Study population
Seventeen right handed patients with diagnosis of idiopathic
Parkinson’s disease, according to the United Kingdom Parkinson’s
Disease Society Brain Bank Criteria (Hughes et al., 1992), were
enrolled. Inclusion criteria were: (a) Hoehn and Yahr scale score
of at least 2 in OFF (Hoehn and Yahr, 1967); (b) disease duration
of at least 4 years; (c) obligatory treatment with levodopa for at
least 1 year, add-on treatment with a dopamine agonist and/or
entacapone and/or a MAO-B inhibitor is permitted; (d) no or only
slight or intermittent tremor present in OFF according to the Uni-
fied Parkinson’s Disease Rating Scale III (UPDRSIII) tremor scores
(item 20 <=5 and item 21 <=2) (Fahn and Elton, 1987) (e) the pres-
ence of LID, according to the Unified Parkinson’s Disease Rating
Scale IV (UPDRSIV) (Fahn and Elton, 1987) criteria, is permitted
but not required; (f) absence of a serious neuropsychiatric disorder
according to the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-5: American Psychiatric Association); (g) an optimal
and stable medication dose for at least 4 weeks preceding inclu-
sion; (h) no contra-indications for rTMS (Rossi et al., 2009). Patient
demographics and characteristics are listed in Table 1.
The Ethics Committee of UZ Brussel approved the study, and
written informed consent was obtained from all patients. Treat-
ment remained unchanged throughout the study period.2.2. Experimental procedures
Each experimental condition (real and sham) was performed
after a 12 hours overnight dopaminergic treatment withdrawal
(practically defined OFF). Patients’ motor disability and dyskinesias
were rated prior to the imaging procedure, using the UPDRSIII and
UPDRSIV scales, respectively (Fahn and Elton, 1987). Handedness
was determined according to the Edinburgh Handedness Inventory
(Oldfield, 1971). Subsequently, patients were accompanied to the
radiology department and prepared for their structural Magnetic
Resonance Imaging (MRI) and baseline 1H Magnetic Resonance
Spectroscopy (MRS) session (see below). Upon completion, LF rTMS
was delivered to the right pre-SMA according to our rTMS protocol
(see below), followed by a second 1H MRS session. Following a
cross-over design, patients were randomized to first receive real
Table 1
Patients’ baseline characteristics.
All Dyskinesia No dyskinesia p-values
Gender (female/male) 6/11 4/5 2/6 0.40a
Age (years) 70.94 (10.17) 72.89 (9.85) 68.75 (10.73) 0.42b
Disease duration (years) 10.59 (5.18) 10.11 (4.37) 11.13 (6.24) 0.70b
Hoehn and Yahr OFFy 2 (2) 3 (2) 2 (1) 0.335c
UPDRSIII OFF 23.00 (6.98) 25.78 (7.79) 19.87 (4.58) 0.081b
LID Yes/No 9/8 9 8
Daily equivalent levodopa dose (mg) 880.59 (413.77) 876.67 (410.09) 885.00 (446.19) 0.969b
RMT (%) 56.76 (4.33) 55.22 (3.77) 58.50 (4.50) 0.12b
Baseline tNAA/tCryy 1.15 (0.11) 1.11 (0.10) 1.21 (0.11) 0.06b
Baseline tCho/tCryy 0.22 (0.03) 0.22 (0.03) 0.22 (0.03) 0.57b
y Data are presented as mean (SD) or median values (range).




1294 A. Flamez et al. / Clinical Neurophysiology 130 (2019) 1292–1298or sham rTMS by flipping a coin. To avoid carry-over effects of
rTMS a time window of at least 1 week was introduced between
sessions (Rossi et al., 2009). Medical treatment was kept stable
throughout the duration of the trial.2.2.1. rTMS stimulation protocol
1 Hz rTMS was delivered with a Magstim high-speed magnetic
stimulator (Magstim Company Limited, Wales, UK) through a
70 mm figure-of eight-shaped coil to the right pre-
supplementary motor area. The position of the TMS coil on the par-
ticipant’s head to target the pre-SMA, was determined using the
3D-MRI localization method (Peleman et al., 2010) at [5, 2, 62]
(MNI coordinates). Before applying rTMS and acquiring MRS imag-
ing, the patient’s Resting Motor Threshold (RMT) was determined
in the Abductor Pollicis Brevis (APB) muscle, contralateral to the
magnetic stimulation of the motor cortex. The RMT for eliciting
responses in the relaxed muscle was defined as the minimal inten-
sity of stimulation capable of inducing motor evoked potentials
greater than 50 l V peak-to-peak in at least 5 of 10 consecutive tri-
als. Upon completion of the baseline MRS session (T0) a series of
1000 pulses at a rate of 1 Hz (duration of 16 minutes) with an
intensity of 90% of the RMT were delivered to the right pre-SMA,
followed by the second MRS session (T1). During sham stimulation,
a sham coil identical to the real coil was used providing the same
auditory stimuli, but no cortical stimulation.2.2.2. 1H MR spectroscopy
Imaging data were obtained using a Philips 3 T MRI scanner
(Ingenia, Best, The Netherlands). First an anatomical scan was
taken (3D T1 TFE, FOV = 240  240  200 mm3, resolu-
tion = 1  1  2 mm3, TR = 12 ms, TE = 3.85 ms, flip angle = 10,
turbo factor = 240). Second, a 1H MRS scan was taken of the right
pre-SMA region (SV PRESS, VOI = 20  20  20 mm3, TR = 2000 ms,
TE = 38 ms, NSA = 128, sample frequency = 2000, samples = 1024)
(Fig. 1A and B). The pre-SMA was visually determined and we used
a voxel size of 20  20  20 mm3. MRS data were analyzed using
TARQUIN following the default processing pipeline (Wilson et al.,
2011). The basic brain metabolite set of TARQUIN consisted of -
CrCH2, alanine, aspartate, creatine (Cr), GABA, Glycerophospho-
choline (GPC), glucose, glutamine, glutamate, gua , inositol, lactate,
4 lipids, 5 macromolecules, N-acetylaspartate (NAA), N-
acetylaspartylglutamate (NAAG), Phosphocholine (PCh), Phospho-
creatine (PCr), scyllo-inositol and taurine. The results for the
metabolites coming out of TARQUIN were referenced to an unsup-
pressed water spectrum. Since it was not possible to trace back the
spectro volume on the anatomical scan, we did not correct for par-
tial volume effects. Besides the individual water-referencedmetabolite estimates, TARQUIN calculated total NAA (tNAA) as
NAA + NAAG, total Cho (tCho) as GPC + PCh and total Cr (tCr) as
Cr + PCr.2.3. Statistical analysis
All analyses were carried out in SPSS 24 (Statistical Package for
the Social Sciences; IBM SPSS Statistics for Windows, Version 24.0,
IBM Corp., Armonk, NY). The significance level was set at p < 0.05,
two-tailed, for all analyses. Where necessary, we applied the
Greenhouse–Geisser correction to ensure the assumption of
sphericity. Baseline characteristics were evaluated using paramet-
ric and non-parametric statistics where appropriate.
For the effects of one LF-rTMS session on 1H MR spectroscopy
measurements, only a priori hypotheses were tested. First, we cal-
culated the total tNAA/tCr ratio (t(NAA + NAAG)/t(Cr + PCr)) and
the total tCho/tCr ratio (t(GPC + PCh) /t(Cr + PCr)) for the right
pre-SMA ROI. Second, to evaluate baseline differences between
PD patients with and without dyskinesia we calculated the mean
of the two baseline measurements for a given patient (before the
sham and real LF-rTMS session) for tNAA/tCr and tCho/tCr levels.
Third, to examine the effect of one session of LF-rTMS on right
pre-SMA metabolism, we performed two separate mixed ANCO-
VA’s including the individual neurometabolite ratios as the depen-
dent variables and with Time (before vs. after LF-rTMS) and
Stimulation (real vs. sham) as the within subjects factors. Dyskine-
sia (yes vs. no) was the between-subjects factor and given that
Parkinson’s disease duration seems to play an important role in
pre-SMA’s neurochemistry, the latter was introduced as covariate
(Camicioli et al., 2007; Martin et al., 2008). Significant interaction
effects were followed-up with separate univariate analyses of vari-
ance, correlation analyses, and T-tests where appropriate.3. Results
We found no baseline statistical differences concerning age, dis-
ease duration, UPDRSIII in OFF and equivalent levodopa dosages
between patients with or without dyskinesias (p’s > 0.05). Also
the time interval (in days) between the number of PD patients first
receiving real (n = 8, 13.13 days (SD = 6.94)) and those patients
first receiving sham (n = 9, 13.22 days (SD = 6.50)) was not signifi-
cant t (15) = 0.03, p = 0.98). We did however observe a trend that
PD patients with dyskinesia had lower mean baseline tNAA/tCr
levels compared to PD patients without dyskinesia (p = 0.06), but
not for tCho/tCr (p = 0.57). Patients’ characteristics are listed in
Table 1. tNAA/tCr and tCho/tCr ratios for the right pre-SMA are pro-
vided in Table 2.
Fig. 1. (A) Example of pre-SMA voxel placement, and (B) of a typical spectrum obtained in one of our patients. Depiction of plots showing the original measured spectrum
(black lines), the result of the model fitting (green lines) and the fitting results for some individual metabolites (red lines). TARQUIN calculates total NAA (tNAA) as NAA
+ NAAG, total Cho (tCho) as GPC + PCh and total Cr (tCr) as Cr + PCr. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Table 2
Right pre-SMA tNAA/tCr and tCho/tCr ratio’s.
Sham baseline Sham post LF rTMS Real baseline Real post LFrTMS
All
tNAA/tCr 1.12 (0.18) 1.13 (0.21) 1.19 (0.15) 1.24 (0.13)
tCho/tCr 0.22 (0.04) 0.21 (0.04) 0.22 (0.02) 0.23 (0.04)
Dyskinesia
tNAA/tCr 1.07 (0.15) 1.04 (0.17) 1.14 (0.15) 1.21 (0.14)
tCho/tCr 0.21 (0.04) 0.21 (0.05) 0.22 (0.03) 0.22 (0.04)
No Dyskenisia
tNAA/tCr 1.17 (0.21) 1.23 (0.22) 1.24 (0.14) 1.27 (0.12)
tCho/tCr 0.23 (0.04) 0.21 (0.03) 0.22 (0.03) 0.23 (0.04)
Presented values are means and standard deviations of the ratio’s of following metabolites: tNAA (sum of the absolute concentrations N-acetylaspartate + N-acetylas-
partylglutamate); tCho (sum of absolute concentrations phosphocholine and glycerophosphocholine); tCr (sum of the absolute concentrations creatine + phosphocreatine).
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did not show a main effect of Time and Disease duration
(p’s > 0.05). However, we did observe a significant main effect of
Dyskinesia (F(1,14) = 6.58, p = 0.02) and Stimulation (F(1,14)
= 8.49, p = 0.01). Pairwise comparisons showed a marginal signifi-
cant difference (p = 0.06) between sham (1.13, SE = 0.03) and real
stimulation (1.22, SE = 0.03) and a significant difference (p = 0.02)
between PD patients with Dyskinesia (1.12, SE = 0.03) and those
without Dyskinesia (1.23, SE = 0.03). Besides a significant 2-way
interaction effect between Stimulation and Disease duration
(F(1,14) = 5.14, p = 0.04), the other 2-way interactions between
Time and Disease duration, between Time and Dyskinesia, betweenStimulation and Dyskinesia, between Time and Stimulation, and
between Dyskinesia and Disease duration were not significant
(p’s > 0.05). Also, the 3-way interaction effects between Time,
Stimulation, and Disease duration, and between Time, Stimulation,
and Dyskinesia were not significant (p’s > 0.05).
The mixed ANCOVA for the tCho/tCr ratio in the right pre-SMA
showed a significant main effect of Time (F(1,14) = 4.70, p = 0.048),
but not for Stimulation, Dyskinesia, and Disease duration
(p’s > 0.05). We observed a significant 2-way interaction effect
between Time and Disease duration (F(1,14) = 6.95, p = 0.02) and
between Time and Stimulation (F(1,14) = 19.30, p < 0.01), but not
for the remaining 2-way interaction effects (p’s > 0.05). However,
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and Dyskinesia was not significant (F(1,14) = 1.95, p = 0.18), we
found a significant 3-way interaction effect between Time, Stimu-
lation, and Disease duration (F(1,14) = 16.46, p < 0.01).
To further examine this significant three-way interaction effect,
we calculated the differences in tCho/tCr changes before and after
stimulation for real and sham LF-rTMS separately (real delta tCho/
tCr = real post tCho/tCr real pre tCho/tCr; sham delta tCho/
tCr = sham post tCho/tCr sham pre tCho/tCr), and the neu-
rometabolic differences between real and sham stimulation sepa-
rately (delta pre tCho/tCr = real pre tCho/tCr  sham pre tCho/
tCr; delta post tCho/tCr = real post tCho/tCr  sham post tCho/
tCr). Correlation analyses showed a significant negative association
between Disease duration and the change after one real LF-rTMS
session (real delta tCho/tCr) (r = 0.73, p < 0.01) (see Fig. 2A), indi-
cating that the longer duration of PD, the less this affects tCho/tCr
in the right pre-SMA. In line with this assumption, the correlation
analysis between Disease duration and the difference between
having had one real or one sham LF-rTMS session (delta post
tCho/tCr) showed that the longer the presence of PD the less the
effect of one real LF-rTMS session on the right pre-SMA tCho/tCr
ratio (r = 0.59, p = 0.01) (see Fig. 2B). No significant correlations
were observed between Disease duration and the change after
one sham LF-rTMS session (sham delta tCho/tCr) (r = 0.26,
p = 0.31).
4. Discussion
Although the effect of LF rTMS on brain metabolites has been
studied in healthy volunteers and tinnitus (Cacace et al., 2017;
Bridges et al., 2018), to our knowledge, this is the first study inves-
tigating the effects of LF rTMS on brain metabolism in PD patients.
We evaluated the effect of a single session of right pre-SMA LF
rTMS on tNAA/tCr and tCho/tCr pre-SMA ratios in late stage Parkin-
son’s disease patients in their practically defined OFF state.
Although we found a main effect of Stimulation and Dyskinesia,
there was no significant interaction with Time, suggesting that one
session of LF rTMS does not affect tNAA/tCr ratios. These observa-
tions imply that, at least in this population, one LF rTMS session
appears to be a safe intervention showing no negative effects on
neuronal integrity. The significant 2-way interaction effect
between Stimulation and Disease duration insinuates that unre-Fig. 2. Influence of disease duration on the effect of one session of real LF rTMS on pre-SM
the change after one real LF-rTMS session (real delta tCho/tCr) (r = 0.73, p < 0.01). (B) Si
having had one real or one sham LF-rTMS session (delta post tCho/tCr) (r = 0.59, p = 0lated to Time, the duration of PD illness is related to a difference
between sham and real stimulation. However, because we always
measured before and after LF-rTMS stimulation (real and sham),
and we used a within subject’s design (so no difference in groups),
this can only be coincidence (probably due to a random difference
between sham and real tNAA/tCr ratios). Since we did not include a
matched healthy control population in our study, we cannot com-
ment on whether the tNAA/tCr ratio in our patients is different
from controls. We did in our population, however, find a trend
towards lower baseline pre-SMA tNAA/tCr ratios in PD patients
with dyskinesias. Since it has been shown that the tNAA/tCr ratio
in the pre-SMA in early untreated PD patients is not different from
healthy controls (Martin et al., 2008), but that it is significantly
reduced in a more advanced treated PD population (Camicioli
et al., 2007), our findings indicate that our patients suffering from
dyskinesias are in a slightly more advanced PD stage, which is not
reflected in their other baseline characteristics (see Table 1).
The effect of one session of 1 Hz rTMS at the right pre-SMA on
pre-SMA tCho/tCr ratio is more complex. Unrelated to the presence
of dyskinesias, real LF rTMS (and not sham) significantly affected
the tCho/tCr ratio, but only when taking disease duration into
account. The shorter the PD duration, the stronger the observed
effects. This indicates that in the early stages of the advanced
stages of PD, membrane turnover (breakdown and/or synthesis)
at the pre-SMA could still be influenced by one session of real LF
rTMS, suggesting that at least some brain plasticity is still pre-
served. Most of the brain’s choline is bound to membrane phos-
pholipids, such as phosphatidylcholine, and not moving freely in
solution, therefor largely invisible on 1H MRS (Klein, 2000).
Increased phosphocholine formation from free choline may indi-
cate de novo membrane biosynthesis, but also an increased mem-
brane breakdown, releasing membrane bound choline into the
cytosol. This assumption is in line with the observation that a
dopaminergic treatment is able to restore the Cho/Cr ratio in the
motor cortical regions (Lucetti et al., 2007). Our LF rTMS findings
also indicate that not the presence of levodopa induced dyskinesias
is of importance but the disease duration. This is aligned with find-
ings in other neuropsychiatric illnesses that disease duration is a
negative influential factor for beneficial clinical outcome after
rTMS (Wu and Baeken, 2017).
There are several limitations to our study. First, we chose to
evaluate the effect of an intervention (before and after LF rTMS)A tCho/tCr ratios. (A) Significant negative association between Disease duration and
gnificant negative correlation between Disease duration and the difference between
.01).
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disease patients, in their practically defined OFF state. Because we
did not include a group of PD patients on levodopa during the
experiment, we cannot comment on its influence on the neu-
rometabolites examined. Although we observed a marginally main
effect of Stimulation - with increased tNAA/tCr ratios after real LF
rTMS - there was no significant interaction with Dyskinesia. This
indicates that one session of LF rTMS does not affect patients with
or without levodopa induced dyskinesias differently. Notwith-
standing that this observation may suggest that real LF-rTMS on
the right preSMA could locally enhance metabolic processes,
whether this results in clinical improvements remains to be deter-
mined in larger patient samples treated with multiple LF rTMS ses-
sions. It has been demonstrated that in early untreated and more
advanced, but treated, PD patients the pre-SMA Cho/Cr ratio is
not different from healthy controls (Camicioli et al., 2007; Martin
et al., 2008). Since we did not include a healthy control population,
comparison with previous studies is difficult. Second, although the
selection of one a priori chosen brain area implicated in the patho-
physiology of PD and the well-defined selection of our PD sample
must be considered as study strengths, the relatively small sample
limits general conclusions. Third, a multiple session rTMS approach
could have yielded larger effects on metabolites. Fourth, although
we deduce that tCho/tCr ratio increases are related to potential
neuroplastic processes, this increased ratio could also point to
increased membrane breakdown, releasing membrane bound cho-
line into the cytosol. And last, since it was not possible to trace
back the spectro volume on the anatomical scan, we did not correct
for partial volume effects.
To summarize, one LF rTMS session at the right pre-SMA in late
stage Parkinson patients does not alter neuronal integrity, but
influences membrane turnover, inversely correlated with disease
duration. Importantly, this neurophysiological effect was not
dependent on the presence of dyskinesias. Given the relatively
small sample size, even if we did not observe serious adverse
advance clinically and on the brain level, we cannot firmly con-
clude that our LF-rTMS is a safe procedure. Although our sample
was very similar to other studies applying single rTMS sessions
in PD patients, clearly larger clinical studies with different neuro-
biological measurements are needed. Because the effect of LF rTMS
on tCho/tCr ratio seems more important in patients with shorter
disease duration, PD patients may benefit more from this non-
invasive neurostimulation in the earlier stages of the disease. Of
course, larger LF rTMS treatment studies applying multiple ses-
sions, targeting the pre-SMA are needed to substantiate these
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